Premium
Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti‐ HCV therapy (ledipasvir/sofosbuvir)
Author(s) -
Murakami Naoka,
Ding Yanli,
Cohen David J.,
Chandraker Anil K.,
Rennke Helmut G.
Publication year - 2018
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12959
Subject(s) - medicine , membranous nephropathy , sofosbuvir , rituximab , ledipasvir , nephrotic syndrome , gastroenterology , renal biopsy , proteinuria , nephropathy , plasmapheresis , immunology , tacrolimus , kidney , hepatitis c virus , transplantation , antibody , virus , endocrinology , ribavirin , diabetes mellitus
Direct‐acting antiviral agents ( DAA s) are very effective therapy for chronic hepatitis C infection, and have revolutionized the treatment of hepatitis C in kidney allograft recipients. Although well tolerated in general, rare renal complications have been reported. We describe a case of recurrent membranous nephropathy and acute cellular rejection in a kidney allograft recipient after DAA (ledipasvir/sofosbuvir) therapy, whose allograft function had been stable for more than 30 years. The patient was presented with nephrotic range proteinuria with stable creatinine. The kidney allograft biopsy revealed recurrent membranous nephropathy with fine granular deposits of IgG1/IgG4 codominance and positive phospholipase A2 receptor ( PLA 2R) staining. The patient was treated with pulse steroid and rituximab, leading to a decrease in proteinuria. As DAA s are more frequently used, physicians should be aware of immune‐related renal complications.